Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Wolff

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
ESMO Open|December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancerS M Tolaney, N Tung, A C Wolff, et al.
Clinical Pharmacology and Therapeutics|May 30, 2008
Pharmacogenetic pathway analysis of docetaxel eliminationS D Baker, J Verweij, G A Cusatis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerE L Mayer, V Abramson, R Jankowitz, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022R A Freedman, H M Heiling, T Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
ESMO Open|December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancerS M Tolaney, N Tung, A C Wolff, et al.
Clinical Pharmacology and Therapeutics|May 30, 2008
Pharmacogenetic pathway analysis of docetaxel eliminationS D Baker, J Verweij, G A Cusatis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerE L Mayer, V Abramson, R Jankowitz, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022R A Freedman, H M Heiling, T Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Pageof 5